COMMUNIQUÉS West-GlobeNewswire

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
27/04/2026
Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across [...]
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
27/04/2026
Expect to complete BLA submission in second half of 2026; anticipate launch in first half of 2027, if approved CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading [...]
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
27/04/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 12, 2026 NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
27/04/2026
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today [...]
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
27/04/2026
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and [...]
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
27/04/2026
$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with [...]
Fangzhou Publishes 2025 Annual Report, Advancing AI-Powered Chronic Care Strategy for 2026
27/04/2026
SHANGHAI, April 27, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, published its 2025 Annual Report, following the [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
27/04/2026
COPENHAGEN, Denmark, April 27, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, [...]
Novo Nordisk A/S - share repurchase programme
27/04/2026
Bagsværd, Denmark, 27 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Dark Horse Consulting Group and Porton Advanced Announce Memorandum of Understanding Providing a Streamlined Path to Conducting IITs in China
27/04/2026
WALNUT CREEK, Calif. and SUZHOU, China, April 26, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Porton Advanced, a [...]
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU
27/04/2026
Pratteln, Switzerland, April 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive [...]
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
27/04/2026
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi 1 Rhapsido recommended in 2026 International Urticaria [...]
OSE Immunotherapeutics se félicite de l'octroi de la désignation de médicament orphelin par la FDA du pegrizeprument (VEL-101) pour la prévention du rejet d’organe dans la transplantation cardiaque
27/04/2026
Nantes, le 27 avril, 7h30 CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) se félicite aujourd’hui de l’annonce faite par son partenaire Veloxis Pharmaceuticals, Inc., rapportant que la U.S. Food and [...]
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
27/04/2026
Nantes, France, April 27, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S. Food and Drug [...]
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
26/04/2026
MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the [...]
C3 Davos of Healthcare™ Silicon Valley Summit Opens Tomorrow in Sunnyvale with KFSH
26/04/2026
SUNNYVALE, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- The C3 Davos of Healthcare™ Silicon Valley Summit will begin tomorrow at the Plug and Play Tech Center in Sunnyvale, California, under the theme “Healthtech [...]
HeroUp Claims Evaluated: Investigating the Supplement Facts About Hero Up Capsules for Hardero Male Enhancement Support
26/04/2026
A 2026 overview of HeroUp's proprietary blend, supplement facts, 800 mg ingredient profile, pricing, and 180-day guarantee Lakeland, FL, April 25, 2026 (GLOBE NEWSWIRE) -- This content contains affiliate links. If a [...]
Quad ED Under Investigation: Safe Clinician-Prescribed ED Medication Using Sildenafil, Tadalafil, Vardenafil and Apomorphine for Men
26/04/2026
A consumer-informational overview addressing common search questions about the Quad 4-in-1 compounded sublingual ED formulation — how clinician-prescribed Sildenafil, Tadalafil, Vardenafil, and Apomorphine work together [...]

Pages